Bio-Rad launches validated antibodies for rare cell and circulating tumor cell enumeration

Bris­tol My­ers Squibb is bring­ing its CAR-T cell ther­a­py to adults with re­lapsed or re­frac­to­ry chron­ic lym­pho­cyt­ic leukemia or small lym­pho­cyt­ic lym­phoma, thanks to an

CMS did not make a na­tion­al cov­er­age de­ter­mi­na­tion for PrEP by the ex­pect­ed date of Oct. 10, but a fi­nal de­ci­sion will be com­ing lat­er,